At-risk hep B crowd ignores jab; immatics touts positive midstage data on colon cancer vax;

> Investigators have concluded that more than half of adults who run a high risk of getting hepatitis B are never vaccinated against the virus. The study tracked specific groups who were more or less likely to get the jab. Report

> Canadian health officials are urging males in the country ages 9 to 26 to get vaccinated against HPV, extending a recommendation already in place for females. Story

> Germany's immatics says it gained positive midstage data for an experimental oncology vaccine targeting colorectal cancer. Release

> Investigators concluded that serious allergic reactions in children are rare after a vaccination. Story

> After fighting whooping cough outbreaks for two decades, California officials say they got through 2011 without a single death. Article

Suggested Articles

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.

As top players race to deliver COVID-19 vaccines, Russia approved a locally developed shot based on skimpy data. Experts called it a political stunt.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan